Neogen (NEOG) to Release Earnings on Wednesday

Neogen (NASDAQ:NEOG) will likely be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $225.27 million for the quarter. Neogen has set its FY 2025 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Neogen (NASDAQ:NEOG) last issued its earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.12. The firm had revenue of $231.30 million during the quarter, compared to analyst estimates of $227.16 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The business’s revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.11 earnings per share. On average, analysts expect Neogen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Neogen Stock Performance

Shares of NASDAQ:NEOG opened at $7.85 on Tuesday. Neogen has a one year low of $7.47 and a one year high of $18.58. The firm has a market cap of $1.70 billion, a PE ratio of -3.58 and a beta of 1.57. The firm’s 50 day simple moving average is $9.72 and its 200-day simple moving average is $12.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77.

Insider Buying and Selling

In other Neogen news, CEO John Edward Adent bought 23,035 shares of Neogen stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, with a total value of $254,076.05. Following the transaction, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at approximately $2,968,878.92. This represents a 9.36 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David H. Naemura bought 14,800 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were bought at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the transaction, the chief financial officer now owns 61,434 shares in the company, valued at $682,531.74. The trade was a 31.74 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Guggenheim initiated coverage on Neogen in a research note on Thursday, December 19th. They set a “buy” rating and a $15.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $13.00 target price (down from $16.50) on shares of Neogen in a report on Tuesday, January 21st.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.